EUVIMEDEUVIMED entdecken
Crossref

Morroniside delays the progression of non-alcoholic steatohepatitis by promoting AMPK-mediated lipophagy

Cong Zhang, Qiao Tong, Kexin Liu, Tongyun Mao, Yingying Song, Yaqin Qu, Xin Chen, Zhenpeng Qiu

Phytomedicine · 2024-07 · 129 · 155703

DOI: 10.1016/j.phymed.2024.155703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024-07. Verfasst von Cong Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Basic Medical Sciences, China Three Gorges University, Yichang 443002, China. Electronic address: zzcyyc520@126.com. Hauptthemen laut MEDLINE: AMP-Activated Protein Kinases, Diet, High-Fat, Lipid Metabolism, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Non-alcoholic steatohepatitis (NASH), the inflammatory subtype in the progression of non-alcoholic fatty liver disease, is becoming a serious burden threatening human health, but no approved medication is available to date. Mononoside is a natural active substance derived from Cornus officinalis and has been confirmed to have great potential in regulating lipid metabolism in our previous studies. However, its effect and mechanism to inhibit the progression of NASH remains unclear. PURPOSE: Our work aimed to explore the action of mononoside in delaying the progression of NASH and its regulatory mechanisms from the perspective of regulating lipophagy. METHODS AND RESULTS: Male C57BL/6 mice were fed with a high-fat and high-fructose diet for 16 weeks to establish a NASH mouse model. After 8 weeks of high-fat and high-fructose feeding, these mice were administrated with different doses of morroniside. H&E staining, ORO staining, Masson staining, RNA-seq, immunoblotting, and immunofluorescence were performed to determine the effects and molecular mechanisms of morroniside in delaying the progression of NASH. In this study, we found that morroniside is effective in attenuating hepatic lipid metabolism disorders and inflammatory response activation, thereby limiting the progression from simple fatty liver to NASH in high-fat and high-fructose diet-fed mice. Mechanistically, we identified AMPK signaling as the key molecular pathway for the positive efficacy of morroniside by transcriptome sequencing. Our results revealed that morroniside maintained hepatic lipid metabolism homeostasis and inhibited NLRP3 inflammasome activation by promoting AMPKα phosphorylation-mediated lipophagy and fatty acid oxidation. Consistent results were observed in palmitic acid-treated cell models. Of particular note, silencing AMPKα both in vivo and in vitro reversed morroniside-induced lipophagy flux enhancement and NLRP3 inflammasome inhibition, emphasizing the critical role of AMPKα activation in the effect of morroniside in inhibiting NASH progression. CONCLUSION: In summary, the present study provides strong evidence for the first time that morroniside inhibits NASH progression by promoting AMPK-dependent lipophagy and inhibiting NLRP3 inflammasome activation, suggesting that morroniside is expected to be a potential molecular entity for the development of therapeutic drugs for NASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AMP-Activated Protein KinasesDiet, High-FatLipid MetabolismNon-alcoholic Fatty Liver DiseaseAnimalsHumansMaleMiceCornusDisease Models, AnimalDisease ProgressionFructoseGlycosidesInflammasomesLiverMice, Inbred C57BLNLR Family, Pyrin Domain-Containing 3 Protein

Stichwörter der Autor:innen

AMPKαInflammatory responseLipophagyMorronisideNon-alcoholic steatohepatitis

Substanzen

AMP-Activated Protein KinasesFructoseGlycosidesInflammasomesmorronisideNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouse

Autor:innen und Institutionen

  • College of Basic Medical Sciences, China Three Gorges University, Yichang 443002, China. Electronic address: zzcyyc520@126.com.
  • Hangzhou Xixi Hospital, Zhejiang Chinese Medical University, Hangzhou 310023, China.
  • Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan 430072, China.
  • Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
  • Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China.
  • Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China; Hubei Shizhen Laboratory, Wuhan 430061, China.

Zitieren

APA

Zhang, C., Tong, Q., Liu, K., Mao, T., Song, Y., Qu, Y., Chen, X., & Qiu, Z. (2024). Morroniside delays the progression of non-alcoholic steatohepatitis by promoting AMPK-mediated lipophagy. Phytomedicine, 129, 155703. https://doi.org/10.1016/j.phymed.2024.155703

Vancouver

Zhang C, Tong Q, Liu K, Mao T, Song Y, Qu Y, et al. Morroniside delays the progression of non-alcoholic steatohepatitis by promoting AMPK-mediated lipophagy. Phytomedicine. 2024;129:155703. doi:10.1016/j.phymed.2024.155703

BibTeX
@article{Zhang2024,
  author = {Zhang, Cong and Tong, Qiao and Liu, Kexin and Mao, Tongyun and Song, Yingying and Qu, Yaqin and Chen, Xin and Qiu, Zhenpeng},
  title = {Morroniside delays the progression of non-alcoholic steatohepatitis by promoting AMPK-mediated lipophagy},
  journal = {Phytomedicine},
  year = {2024},
  volume = {129},
  pages = {155703},
  doi = {10.1016/j.phymed.2024.155703}
}
Kostenlos starten →